GO:0030165 PDZ domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030165 (PDZ domain binding) is a molecular function describing the binding of a protein or ligand to a PDZ domain, a compact protein-protein interaction module found in diverse signaling proteins.
• PDZ domain binding is typically mediated by short C-terminal motifs or internal sequences in partner proteins, and structural studies show multiple binding conformations and unusual interaction modes.
• PDZ domain binding organizes scaffold complexes that control ion transport, cell polarity, tight junction formation, and cytoskeletal anchoring.
• Disease-relevant PDZ interactions include CASK in neurodevelopmental disorders, PICK1 in osteoclast differentiation, and PTEN-PTPN13 in cancer signaling.
• Phosphoinositides and phosphorylation regulate PDZ domain scaffold assembly and ligand selection, making these interactions dynamic and tunable.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of PDZ domain binding in cells and organisms.
Description
PDZ domain binding (GO:0030165) is a molecular function that describes the binding of a protein or peptide ligand to a PDZ domain, a small protein-interaction module present in many signaling and scaffolding proteins. PDZ domains are among the most common modular domains in the human proteome and typically recognize short C-terminal sequences, although internal motifs and unusual binding modes have also been structurally characterized. Because PDZ domain binding nucleates multiprotein complexes, it is central to processes such as ion transport regulation, cell polarity, and junction assembly. Researchers study PDZ domain binding to understand how signaling specificity is achieved and how mutations in PDZ-containing proteins contribute to disease. Structural and biochemical work has revealed that PDZ domains can adopt multiple binding conformations and can be regulated by lipids and post-translational modifications. This article summarizes the definition, mechanism, key genes, disease links, and experimental methods for GO:0030165.
PDZ domain binding At A Glance
| GO ID | GO:0030165 |
|---|---|
| GO term | PDZ domain binding |
| Ontology | molecular_function |
| Synonym | DHR-domain binding; GLGF-domain binding |
| Definition | Binding to a PDZ domain of a protein, a domain found in diverse signaling proteins. |
| Major function | Mediates protein-protein interactions that scaffold signaling complexes, often via C-terminal peptide motifs. |
| Structural feature | PDZ domains adopt a compact fold with a peptide-binding groove; crystal structures reveal unusual binding interactions. |
| Regulation | Phosphoinositides and phosphorylation can modulate PDZ scaffold assembly and ligand binding. |
| Disease relevance | Mutations affecting PDZ binding are linked to neurodevelopmental disorders, bone disease, and cancer. |
What Is GO:0030165?
In your own words, GO:0030165 (PDZ domain binding) is the molecular function of selectively and non-covalently interacting with a PDZ domain of a protein. A PDZ domain is a structurally conserved protein module of roughly 80-100 amino acids that is found in diverse signaling proteins and typically binds short peptide motifs, often at the C-terminus of partner proteins. The term is used when the binding event is directed toward the PDZ domain itself, as opposed to binding to a different domain of the same protein. Synonyms include DHR-domain binding and GLGF-domain binding.
Why Is PDZ domain binding Important in Cell Biology?
PDZ domain binding is important because it provides a general mechanism for assembling signaling complexes at specific cellular locations, thereby converting weak individual interactions into high-specificity, spatially organized signaling units. This function underlies the regulation of ion channels and transporters, cell polarity, tight junction formation, and cytoskeletal anchoring. Because PDZ-mediated interactions are frequently disrupted by disease-associated mutations, they are attractive targets for mechanistic studies and therapeutic intervention.
• Organizes multiprotein signaling scaffolds at membranes and junctions.
• Regulates ion transport, including NHE3 association with ezrin and NHERF proteins.
• Controls tight junction formation through claudin C-terminal PDZ-binding motifs.
• Modulates osteoclast differentiation via PICK1 PDZ domain binding to calcineurin B.
• Links PTEN to PTPN13 PDZ domains, affecting tumor suppressor signaling.
• Provides a structural paradigm for understanding modular protein interaction specificity.
• Is a hotspot for patient-derived variants that alter ligand binding, as shown for CASK.
• Enables drug discovery efforts targeting PDZ domain pockets, such as PICK1 inhibitors.
• Serves as a model system for studying how phosphoinositides regulate scaffold proteins.
• Supports CRISPR-based functional genomics of PDZ-mediated pathways.
What Happens During PDZ domain binding?
Ligand recognition and initial contact
In simple terms: First, the PDZ domain finds and grabs a short sequence on its partner protein.
PDZ domain binding typically begins with recognition of a short peptide motif, often at the C-terminus of the partner protein. Structural studies show that the PDZ domain uses a conserved binding groove to engage the ligand, but unusual binding interactions can also occur, expanding the range of recognizable sequences. Patient-derived variants in the CASK PDZ domain can define constraints for ligand binding, indicating that even single residue changes can alter recognition.
Conformational adaptation and multiple binding modes
In simple terms: The PDZ domain can change shape to fit different partners.
PDZ domains are not rigid; they can adopt multiple binding conformations. For example, the PICK1 PDZ domain can bind the small molecule BIO124 in three distinct conformations within its pocket, illustrating conformational plasticity. Such adaptability allows a single PDZ domain to interact with different ligands under different conditions.
Scaffold assembly and complex nucleation
In simple terms: Once bound, the PDZ protein acts as a hub that brings other proteins together.
After ligand binding, PDZ-containing proteins often serve as scaffolds that recruit additional partners. Phosphoinositides and PDZ domain scaffolds cooperate to assemble signaling complexes at specific membrane compartments. This scaffold function is critical for processes such as ion transport regulation, where NHE3 associates with the actin cytoskeleton via ezrin and NHERF PDZ proteins.
Regulation by lipids and post-translational modifications
In simple terms: Lipids and chemical tags can switch PDZ interactions on or off.
PDZ domain binding is regulated by phosphoinositides, which can modulate scaffold assembly and ligand accessibility. Post-translational modifications such as phosphorylation can also influence PDZ-mediated interactions, although the precise mechanisms are context-dependent. This regulation ensures that PDZ scaffolds are dynamic and responsive to cellular signals.
Functional outcomes at cellular junctions and cytoskeleton
In simple terms: The result is often a change in cell structure or transport.
PDZ domain binding directly impacts cellular architecture. For instance, a claudin mutant lacking the COOH-terminal PDZ domain-binding motif fails to support tight junction formation, demonstrating the importance of PDZ interactions for junction integrity. Similarly, PDZ-dependent anchoring of transporters to the cytoskeleton regulates epithelial ion transport.
Key Genes Involved in GO:0030165 PDZ domain binding
The following genes encode proteins whose PDZ domains or PDZ-binding motifs are experimentally linked to GO:0030165.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CASK | PDZ domain-containing scaffold kinase | Patient variants affect ligand binding at its PDZ domain |
| PICK1 | PDZ domain protein regulating trafficking | Binds calcineurin B in osteoclast differentiation; target of BIO124 |
| SLC9A3R1 (NHERF1) | PDZ domain scaffold for NHE3 | Links NHE3 to ezrin and actin cytoskeleton |
| SLC9A3R2 (NHERF2) | PDZ domain scaffold | Cooperates with NHERF1 in NHE3 regulation |
| SLC9A3 (NHE3) | Na+/H+ exchanger | Associates with ezrin and NHERF PDZ proteins |
| EZR | ERM protein linking membrane to actin | Binds NHE3 directly and via NHERF |
| CLDN (claudin family) | Tight junction proteins | C-terminal PDZ-binding motif required for junction formation |
| PTEN | Tumor suppressor lipid phosphatase | Binds PDZ domains of PTPN13 |
| PTPN13 | PDZ domain-containing phosphatase | Interacts with PTEN via PDZ domains |
| CALCINEURIN B (PPP3R1) | Regulatory subunit of calcineurin | Binds PICK1 PDZ domain in osteoclasts |
| BIO124 target (PICK1) | Small molecule binding pocket | Three binding conformations in PICK1 PDZ domain |
| DHR/GLGF motif proteins | Generic PDZ domain proteins | Synonyms reflect conserved domain family |
| Scaffold proteins (generic) | Multiprotein complex assembly | Regulated by phosphoinositides |
| Ion transporter complexes | Epithelial transport | PDZ-dependent anchoring to cytoskeleton |
| Junctional adhesion complexes | Cell-cell adhesion | PDZ motifs in claudins and other junction proteins |
| Signaling scaffolds (generic) | Signal transduction | PDZ domain binding nucleates signaling hubs |
| CASK ligands | Neuronal signaling | Ligand binding constraints defined by patient variants |
How Is PDZ domain binding Regulated?
PDZ domain binding is regulated by multiple mechanisms. Phosphoinositides can directly modulate PDZ domain scaffold assembly and ligand selection, as reviewed in the context of PDZ domain scaffolds. Post-translational modifications, including phosphorylation, can alter the affinity or accessibility of PDZ-binding motifs, although the specific effects depend on the protein pair. Additionally, the conformational plasticity of PDZ domains, exemplified by the multiple binding modes of the PICK1 PDZ domain, provides a structural basis for regulation by small molecules and possibly by cellular signals. Disease-associated mutations in PDZ domains, such as those in CASK, can also change ligand binding constraints, effectively acting as genetic regulators of this function.
PDZ domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CASK | Neurodevelopmental disorders | Patient-derived point mutations in PDZ domain; KO neurons |
| PICK1 | Osteoclast differentiation / bone disease | KO osteoclasts; point-mutation knock-in of PDZ pocket |
| PTEN | Cancer signaling | Knock-in of PDZ-binding motif mutations; KO cancer cell lines |
| CLDN | Epithelial barrier dysfunction | KO of PDZ-binding motif; tight junction assays |
| SLC9A3 (NHE3) | Ion transport disorders | KO epithelial cells; tagged knock-in for localization |
Neurodevelopmental disorders and CASK
Mutations in the CASK PDZ domain can alter ligand binding, and patient-derived variants have been used to define constraints for PDZ domain interactions. This links GO:0030165 directly to neurodevelopmental phenotypes associated with CASK dysfunction.
Bone disease and osteoclast differentiation
The PICK1 PDZ domain binds calcineurin B and regulates osteoclast differentiation, suggesting that PDZ domain binding is relevant to bone remodeling and diseases characterized by abnormal osteoclast activity.
Cancer and PTEN-PTPN13 signaling
PTEN interacts with the PDZ domains of PTPN13, and this interaction may influence tumor suppressor signaling. Disruption of PDZ-mediated PTEN binding could contribute to cancer progression, making it a potential target for mechanistic studies.
Epithelial transport and junctional disorders
PDZ domain binding is essential for NHE3 regulation and tight junction formation. Loss of the claudin C-terminal PDZ-binding motif impairs tight junction formation, which is relevant to epithelial barrier disorders.
From PDZ domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDZ domain binding affect complex assembly? | CRISPR knockout of PDZ domain in target gene |
| Does a patient variant alter ligand specificity? | Point-mutation knock-in of the variant |
| Can a PDZ-binding motif be tracked in live cells? | Tagged knock-in (e.g., GFP) at the endogenous locus |
| Does overexpression of a PDZ domain disrupt signaling? | Overexpression cell model |
| Which genes depend on PDZ-mediated scaffolding? | CRISPR library screening |
| What is the transcriptional response to PDZ disruption? | RNA-seq after knockout or point mutation |
How to Study the PDZ domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | 3D structure of PDZ-ligand complexes | Defining binding modes and unusual interactions |
| NMR spectroscopy | Conformational dynamics | Detecting multiple binding conformations |
| Isothermal titration calorimetry | Binding affinity and thermodynamics | Quantifying PDZ-ligand interactions |
| Affinity proteomics | Endogenous interaction partners | Identifying PDZ domain interactors |
| Fluorescence microscopy | Subcellular localization and junction formation | Assessing PDZ-dependent tight junctions |
| CRISPR knockout | Loss-of-function phenotype | Testing requirement for PDZ domain binding |
| RNA-seq | Transcriptional changes | Profiling downstream effects of PDZ disruption |
| CRISPR library screening | Gene dependencies | Identifying synthetic lethal partners of PDZ pathways |
Structural and biophysical methods
X-ray crystallography and NMR have been used to determine PDZ domain structures and to reveal unusual binding interactions. These methods can also capture multiple binding conformations, as shown for the PICK1 PDZ domain with BIO124.
Binding assays and proteomics
In vitro binding assays, such as isothermal titration calorimetry and surface plasmon resonance, measure affinity and kinetics of PDZ-ligand interactions. Affinity proteomics can identify endogenous PDZ domain interactors, as demonstrated for PTEN-PTPN13 PDZ interactions.
Cell-based imaging and junction assays
Fluorescence microscopy and tight junction permeability assays assess the functional consequences of PDZ domain binding, such as claudin-dependent junction formation. Live-cell imaging of tagged PDZ proteins can reveal dynamic scaffold assembly.
Functional genomics and CRISPR screens
CRISPR knockout and point-mutation models enable causal testing of PDZ domain binding. Library screening can identify genes that depend on PDZ-mediated interactions for growth or signaling, and RNA-seq can profile downstream transcriptional changes.
How CRISPR Can Be Used to Study GO:0030165 PDZ domain binding
Knockout
CRISPR knockout of a PDZ domain-containing gene or of the PDZ domain itself can abolish PDZ domain binding and reveal loss-of-function phenotypes. For example, knocking out CASK or its PDZ domain can test ligand binding constraints observed in patient variants.
Point Mutation
Point mutations that alter specific PDZ domain residues can dissect binding specificity. Patient-derived variants in CASK have been used to define constraints for ligand binding, and CRISPR point-mutation knock-in can recreate these alleles in cell models.
Knock-in
Knock-in of tagged PDZ proteins (e.g., GFP or HA) allows tracking of endogenous complexes and scaffold assembly. This approach is useful for studying dynamic PDZ domain binding at junctions and membranes.
Overexpression
Overexpression of wild-type or mutant PDZ domains can act as dominant-negative or gain-of-function tools to perturb PDZ-mediated signaling. This is particularly useful for testing whether a PDZ interaction is sufficient to drive a phenotype, as seen in studies of PDZ scaffolds.
How EDITGENE Supports PDZ domain binding Research
Researchers studying PDZ domain binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling or disease phenotype. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses rigorously.
Contact EDITGENE today to design your custom CRISPR model for PDZ domain binding research.
Frequently Asked Questions About PDZ domain binding
What is GO:0030165?
GO:0030165 is the Gene Ontology molecular function term for PDZ domain binding, defined as binding to a PDZ domain of a protein, a domain found in diverse signaling proteins.
What is PDZ domain binding?
PDZ domain binding is the non-covalent interaction of a protein or ligand with a PDZ domain, typically via short peptide motifs, to form signaling complexes.
What genes are involved in PDZ domain binding?
Genes include CASK, PICK1, SLC9A3R1 (NHERF1), SLC9A3R2 (NHERF2), SLC9A3 (NHE3), EZR, claudins, PTEN, and PTPN13, among others.
How is PDZ domain binding regulated?
It is regulated by phosphoinositides, post-translational modifications, and conformational plasticity of the PDZ domain.
What diseases are linked to PDZ domain binding?
Diseases include neurodevelopmental disorders (CASK), bone disease (PICK1), cancer (PTEN-PTPN13), and epithelial barrier disorders (claudins).
What methods are used to study PDZ domain binding?
Methods include X-ray crystallography, NMR, isothermal titration calorimetry, affinity proteomics, fluorescence microscopy, and CRISPR-based functional genomics.
Can CRISPR be used to study PDZ domain binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of PDZ domain interactions.
What is the PICK1 PDZ domain?
The PICK1 PDZ domain is a structurally plastic module that can bind small molecules like BIO124 in multiple conformations and interacts with calcineurin B.
How does PDZ domain binding affect tight junctions?
Claudin proteins require their C-terminal PDZ-binding motif for tight junction formation; loss of this motif impairs junction assembly.
Why is PDZ domain binding important for drug discovery?
PDZ domains are attractive drug targets because they mediate specific protein-protein interactions, and small molecules can bind their pockets, as shown for PICK1.
Conclusion
GO:0030165 (PDZ domain binding) is a fundamental molecular function that governs the assembly of signaling complexes, ion transport, cell polarity, and junction formation. Structural and functional studies have revealed remarkable plasticity in PDZ-ligand recognition, and disease-associated mutations underscore its clinical relevance. CRISPR-based models and screening approaches now enable precise causal testing of PDZ domain binding in health and disease.
References
- 1. Tibbe D et al.. 2025. Patient-Derived Variants Define Constraints for Ligand Binding at the PDZ Domain of CASK.. J Neurochem 169(12):e70303 PMID: 41321276
- 2. Stevens AO et al.. 2022. Three Binding Conformations of BIO124 in the Pocket of the PICK1 PDZ Domain.. Cells 11(15) PMID: 35954295
- 3. Cha B et al.. 2008. The epithelial brush border Na+/H+ exchanger NHE3 associates with the actin cytoskeleton by binding to ezrin directly and via PDZ domain-containing Na+/H+ exchanger regulatory factor (NHERF) proteins.. Clin Exp Pharmacol Physiol 35(8):863-71 PMID: 18430067
- 4. Kamano Y et al.. 2018. Binding of PICK1 PDZ domain with calcineurin B regulates osteoclast differentiation.. Biochem Biophys Res Commun 496(1):83-88 PMID: 29305867
- 5. Fujiwara S et al.. 2022. Tight junction formation by a claudin mutant lacking the COOH-terminal PDZ domain-binding motif.. Ann N Y Acad Sci 1516(1):85-94 PMID: 35945631
- 6. Wawrzyniak AM et al.. 2013. Phosphoinositides and PDZ domain scaffolds.. Adv Exp Med Biol 991:41-57 PMID: 23775690
- 7. Elkins JM et al.. 2010. Unusual binding interactions in PDZ domain crystal structures help explain binding mechanisms.. Protein Sci 19(4):731-41 PMID: 20120020
- 8. Sotelo NS et al.. 2015. PTEN-PDZ domain interactions: binding of PTEN to PDZ domains of PTPN13.. Methods 77-78:147-56 PMID: 25448478
